Regulation of osteoclastogenesis by Simon extracts composed of caffeic acid and related compounds: successful suppression of bone destruction accompanied with adjuvant-induced arthritis in rats

2005 ◽  
Vol 125 (3) ◽  
pp. 215-225 ◽  
Author(s):  
Quan Yong Tang ◽  
Toshio Kukita ◽  
Yuki Ushijima ◽  
Akiko Kukita ◽  
Kengo Nagata ◽  
...  
PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e62926 ◽  
Author(s):  
Yen-You Lin ◽  
Yen-Hsuan Jean ◽  
Hsin-Pai Lee ◽  
Wu-Fu Chen ◽  
Yu-Min Sun ◽  
...  

2008 ◽  
Vol 60 (6) ◽  
pp. 723-730 ◽  
Author(s):  
Takako Okumura ◽  
Yoko Murata ◽  
Kana Taniguchi ◽  
Akio Murase ◽  
Aisuke Nii

2004 ◽  
Vol 32 (04) ◽  
pp. 521-530 ◽  
Author(s):  
Jae Yeong Lee ◽  
Joong-Hyun Kim ◽  
Seong Soo Kang ◽  
Chun Sik Bae ◽  
Seok Hwa Choi

This study was performed to assess the efficacy of α-viniferin (Carex humilis Leyss) on adjuvant-induced arthritis in rats. Adjuvant arthritis was induced by a single subcutaneous injection of 0.1 ml complete Freund's adjuvant (CFA) containing 7.5 mg Mycobacterium butyricum suspended in 1 ml sterile paraffin oil into the right hind paw. Forty female Sprague-Dawley rats were injected. Righting reflex was uniformly lost and considered to be the initial point of arthritis development on day 7 after CFA injection. Rats were divided into four groups, and upon development of arthritis, tested groups were orally administered 3 or 10 mg/kg α-viniferin or 10 mg/kg ketoprofen every day for 14 days. The control group was orally administered 2 ml of physiological saline solution. Bone mineral density (BMD), radiological changes and edematous volumes were measured for 35 days. α-viniferin suppressed the development of inflammatory edema, and inhibited the bone destruction, noted with a decrease in BMD ( p <0.05). Hind paw edema volume, BMD and radiological changes did not differ significantly in the ketoprofen and α-viniferin groups during the entire study period. In conclusion, α-viniferin suppressed arthritic inflammation and bony change in rats.


1989 ◽  
Vol 37 (4) ◽  
pp. 1039-1043 ◽  
Author(s):  
Masanori SUGIURA ◽  
Youichiro NAITO ◽  
Yasunari YAMAURA ◽  
Chikara FUKAYA ◽  
Kazumasa YOKOYAMA

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Pankaj S. Kothavade ◽  
Vipin D. Bulani ◽  
Dnyaneshwar M. Nagmoti ◽  
Padmini S. Deshpande ◽  
Nitin B. Gawali ◽  
...  

Objective. Achyranthes asperaLinn. (AA) is used in folklore for the treatment of various inflammatory ailments and arthritis like conditions. Anti-inflammatory activity of saponin rich (SR) fraction of AA has been previously reported. The objective of this study was to assess the antiarthritic effect of SR fraction ofAchyranthes asperain adjuvant-induced arthritic rats.Methods.Arthritis was assessed by arthritis score, paw volume, changes in tibiotarsal joint thickness, hyperalgesic parameters, and spleen and thymus index. Haematological, serum, biochemical, and inflammatory cytokine andin vivoantioxidant parameters were measured on the last day of the study.Results.SR fraction significantly suppressed paw swelling and arthritic score and improved the pain threshold in motility and stair climbing tests. There was a reversal in the levels of altered parameters, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and antioxidant parameters like superoxide dismutase, catalase, glutathione, malondialdehyde, and nitric oxide. SR fraction significantly decreased plasma levels of tumor necrosis factor-alpha and interleukin-6. Moreover, histopathology revealed a significant reduction in synovial hyperplasia, inflammatory cell infiltration, and bone destruction in the joints.Conclusion.These observations explain the therapeutic benefit of SR fraction of AA in suppressing the progression of adjuvant-induced arthritis in rats.


2018 ◽  
Vol 2 (1) ◽  
pp. 11
Author(s):  
Ketherin Ketherin ◽  
Ferry Sandra

Osteoclast activities are responsible for the resorption of bone cells found in several bone diseases, one of which is periodontitis and arthritis. The downregulating signals of Receptor Activator of Nuclear Factor kB (RANK)-RANK Ligand and Tumor Necrosis Factor  (TNF)-a are the major cause of the bone destruction. Studies and experiments have been performed to overcome this matter. Various medications are now available to treat bone-related diseases, targeting the specific aspect of the signaling. Synthetic drugs such as denosumab and bisphosphonates have complex pharmacological action and have been the leading choice in treatment. Evidence in studies proved that natural resources including herbal products have potential application to therapy for bone loss, with caffeic acid and Caffeic Acid Phenethyl Ester (CAPE) showing significant inhibitory results and Chinese herbs such as Herba epimedii (Yín Yáng Huò) and Fructus psoraleae(Bǔ Gǔ Zhī) proved to contain components that give similar effects to estrogen. The purpose of this review is to discuss the therapy value of available synthetic and natural therapeutic agents. Understanding the mechanisms of both agents will not only clarify their function as therapeutic agents, but can also be the key to the treatment of diseases caused by bone resorption by targeting specific aspects of osteoclastogenesis.Keywords: osteoclastogenesis, TNF, RANKL, bone resorption, natural resource, signaling, treatment


1995 ◽  
Vol 182 (2) ◽  
pp. 449-457 ◽  
Author(s):  
J G Conway ◽  
J A Wakefield ◽  
R H Brown ◽  
B E Marron ◽  
L Sekut ◽  
...  

Considerable evidence has associated the expression of matrix metalloproteinases (MMPs) with the degradation of cartilage and bone in chronic conditions such as arthritis. Direct evaluation of MMPs' role in vivo has awaited the development of MMP inhibitors with appropriate pharmacological properties. We have identified butanediamide, N4-hydroxy-2-(2-methylpropyl)-N1-[2-[[2-(morpholinyl)ethyl]-,[S- (R*,S*)] (GI168) as a potent MMP inhibitor with sufficient solubility and stability to permit evaluation in an experimental model of chronic destructive arthritis (adjuvant-induced arthritis) in rats. In this model, pronounced acute and chronic synovial inflammation, distal tibia and metatarsal marrow hyperplasia associated with osteoclasia, severe bone and cartilage destruction, and ectopic new bone growth are well developed by 3 wk after adjuvant injection. Rats were injected with Freund's adjuvant on day 0. GI168 was was administered systemically from days 8 to 21 by osmotic minipumps implanted subcutaneously. GI168 at 6, 12, and 25 mg/kg per d reduced ankle swelling in a dose-related fashion. Radiological and histological ankle joint evaluation on day 22 revealed a profound dose related inhibition of bone and cartilage destruction in treated rats relative to rats receiving vehicle alone. A significant reduction in edema, pannus formation, periosteal new bone growth and the numbers of adherent marrow osteoclasts was also noted. However, no significant decrease in polymorphonuclear and mononuclear leukocyte infiltration of synovium and marrow hematopoietic cellularity was seen. This unique profile of antiarthritic activity indicates that GI168 is osteo- and chondro-protective, and it supports a direct role for MMP in cartilage and bone damage and pannus formation in adjuvant-induced arthritis.


Sign in / Sign up

Export Citation Format

Share Document